Hmm. Still, more sales in the UK in 2-3/23 than in 8/22-1/23. Things take time. Have expectations been unrealistic?
-effectiveness in the field seems even better than in trials
-no side effects
? The US is tight-lipped, no word yet on whether a local study is needed.
Currently, a rather pessimistic scenario regarding long-term sales growth is priced into the share price…